Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 19/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4427010 | 0.92 | ADORA1 (0.74) | ADORA1SLC6A3KDM4EMEN1USP2 | |
| SCHEMBL4435702 | 0.91 | ADORA1 (0.67) | ADORA1SLC6A3KDM4EMEN1USP2 | |
| SCHEMBL13929985 | 0.91 | ADORA1 (0.80) | ADORA1SLC6A3 | |
| SCHEMBL14464879 | 0.90 | ADORA1 (0.84) | ADORA1SLC6A3 | |
| SCHEMBL13929983 | 0.89 | ADORA1 (0.65) | ADORA1SLC6A3KDM4EMEN1USP2 | |
| SCHEMBL4426727 | 0.88 | ADORA1 (0.82) | ADORA1SLC6A3 | |
| SCHEMBL13930005 | 0.88 | ADORA1 (0.66) | ADORA1SLC6A3KDM4EMEN1USP2 | |
| SCHEMBL4432630 | 0.86 | ADORA1 (0.71) | ADORA1SLC6A3 | |
| SCHEMBL14039885 | 0.86 | ADORA1 (0.66) | ADORA1SLC6A3 | |
| SCHEMBL4428654 | 0.86 | ADORA1 (0.67) | ADORA1SLC6A3KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1455785-B1 | SUBSTITUTED 2-THIO-3,5-DICYANO-4-PHENYL-6-AMINOPYRIDINES AND THE USE OF THE SAME | BAYER HEALTHCARE AG (DE) | 2009-03-04 | — | — | EP | disclosed |
| US-20060217373-A1 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | BAYER HEALTHCARE AG (DE) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217373-A1 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | TPMT, QDPR, TUBB6 | ADORA1 998/4885SLC6A3 215/4885KDM4E 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.